| Number of DMPA-SC doses administered to clients | Documents the number of DMPA-SC doses administered to clients, independent from other injectable products Provides the denominator for indicators on new users, switching from DMPA-IM, and switching from other modern methods
|
| Number and percentage of DMPA-SC doses administered to first-time users of modern contraception (“new users”)a | Indicates the total number of new users of modern contraception reached with DMPA-SC and the share of total DMPA-SC doses administered to first-time users, by health system level where relevant Helps determine the extent to which the product is reaching new users, as opposed to users who had previously used another modern method The denominator for the percentage indicator is the number of DMPA-SC doses administered to clients
|
| Number and percentage of DMPA-SC doses administered to clients under age 20, to those ages 20 to 24, and those ages 25 and older (Niger, Senegal, and Uganda only) | Documents the extent to which providers administer DMPA-SC doses to adolescent girls and young women May indicate whether DMPA-SC is an attractive method choice for adolescents and younger women May highlight areas where additional training on provision of family planning methods (and/or injectables) to youth could be needed The denominator for the percentage indicator is the sum of doses administered to clients in each age category
|
| Number and percentage of DMPA-SC doses administered to clients who switched from DMPA-IM (Burkina Faso, Senegal, and Uganda only) | Documents the number and proportion of DMPA-SC doses administered to clients switching from DMPA-IM, in order to track an early concern of stakeholders that DMPA-SC—a more expensive product at the time—would potentially replace DMPA-IM May indicate whether women and/or providers prefer DMPA-SC to DMPA-IM May indicate the need to follow up with providers during supervision to ensure DMPA-SC is not promoted as a replacement for DMPA-IM The denominator for the percentage indicator is the number of DMPA-SC doses administered to clients
|
| Number and percentage of DMPA-SC doses administered to clients who switched from modern methods other than DMPA-IM (Burkina Faso and Senegal only) | Documents the number of DMPA-SC doses administered to clients switching from modern methods other than DMPA-IM The denominator for the percentage indicator is the number of DMPA-SC doses administered to clients
|
| Number of DMPA-IM doses administered to clients | Documents the volume of DMPA-IM doses administered to clients, independent from other injectable products Provides input for the numerator and denominator for the indicator on relative proportions of DMPA-SC and DMPA-IM administered, by level
|
| Relative proportions of DMPA-SC and DMPA-IM administered, by level (where both methods are available) | Documents the relative share of the market comprised of DMPA-SC and of DMPA-IM, by level, where providers offer both methods; may indicate the preference of women and/or providers for each method, though factors such as provider skill level and potential bias should also be considered Numerators include the number of doses of DMPA-SC and DMPA-IM administered to clients; the denominator is the sum of the number of doses of DMPA-SC and DMPA-IM administered to clients
|
| Number and percentage of facilities with a stock-out of DMPA-SC | Documents the extent of DMPA-SC stock-outs and contextualizes trends in DMPA-SC consumption and in the overall method mix Helps identify locations where the distribution system and/orfacility stock management practices may require reinforcement The denominator for the percentage indicator is the number of facilities active in the provision of DMPA-SC that reported during the same period
|
| Number of facilities active in the provision of DMPA-SC that reported this period | Documents the number of facilities that reported on DMPA-SC in a given period Provides input on data completeness Provides the denominator for the percentage of facilities with a stock-out of DMPA-SC
|